Fig. 2.
Overview of human β-globin locus and ex vivo gene therapy for the treatment of SCD and TDT. A) Schematic representation of human β-globin locus and LCR; B) Erythroid-specific expression of β-like globin transgenes using lentiviral vectors; C) Schematic representation of lentiviral gene addition therapy and HBB mutation-independent therapeutic approaches for the treatment of SCD and TDT.